Oesophagitis adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 10,700 adverse event reports that record the MedDRA preferred term Oesophagitis. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 617 reports in the 12 months to June 2026 and 702 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 866 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 617 (under 0.1%) record this term. Reports for patients aged 65 to 74 were 17.4% of the reports that record this term and 11.3% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 136 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Oesophagitis name as a suspect product, in order of name
Drug	Class	Reports with this term
Accutane	Retinoid	49
Acetaminophen		56
Acetylsalicylic Acid		72
Actonel	Bisphosphonate	36
Afinitor	Kinase inhibitor	34
Alendronate	Bisphosphonate	25
Alendronate sodium	Bisphosphonate	98
Alendronic Acid		56
Alimta	Folate analog metabolic inhibitor	33
Allopurinol	Xanthine oxidase inhibitor	35
Amlodipine	Calcium channel blocker	42
Apixaban	Factor Xa inhibitor	62
Aredia		53
Aspirin	Nonsteroidal anti-inflammatory drug	224
Atezolizumab	Programmed death Receptor-1 blocking antibody	52
Avastin	Vascular endothelial growth factor inhibitor	75
Benicar	Angiotensin 2 receptor blocker	79
Benicar HCT	Thiazide diuretic	63
Bevacizumab	Vascular endothelial growth factor inhibitor	206
Boniva		79
Capecitabine	Nucleoside metabolic inhibitor	147
Carboplatin	Platinum-based drug	521
Cetuximab	Epidermal growth factor receptor antagonist	56
Chantix	Partial cholinergic nicotinic agonist	30
Ciprofloxacin	Fluoroquinolone antibacterial	49
Cisplatin	Platinum-based drug	447
Citalopram	Serotonin reuptake inhibitor	45
Clindamycin	Lincosamide antibacterial	64
Clopidogrel	P2Y12 platelet inhibitor	96
Clozapine	Atypical antipsychotic	33
Clozaril	Atypical antipsychotic	42
Cosentyx	Interleukin-17A antagonist	51
Coumadin		33
Crestor	HMG-CoA reductase inhibitor	29
Crizotinib	Kinase inhibitor	34
Cyclophosphamide	Alkylating drug	199
Cyclosporine	Calcineurin inhibitor immunosuppressant	38
Cytarabine	Nucleoside metabolic inhibitor	62
Dexamethasone	Corticosteroid	130
Diclofenac	Nonsteroidal anti-inflammatory drug	61
Diclofenac sodium	Nonsteroidal anti-inflammatory drug	32
Digoxin	Cardiac glycoside	33
Docetaxel	Microtubule inhibitor	128
Doxorubicin	Anthracycline topoisomerase inhibitor	61
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	96
Doxycycline	Tetracycline-class drug	218
Doxycycline hyclate	Tetracycline-class drug	36
Dupixent	Interleukin-4 receptor alpha antagonist	109
Durvalumab	Programmed death Ligand-1 blocker	84
Eliquis	Factor Xa inhibitor	58
Enbrel	Tumor necrosis factor blocker	88
Erbitux	Epidermal growth factor receptor antagonist	75
Erlotinib	Kinase inhibitor	53
Etoposide	Topoisomerase inhibitor	249
Fludarabine	Nucleoside metabolic inhibitor	26
Fluorouracil	Nucleoside metabolic inhibitor	228
Folinic Acid		31
Forteo	Parathyroid hormone analog	25
Fosamax	Bisphosphonate	242
Fulvestrant	Estrogen receptor antagonist	27
Furosemide	Loop diuretic	64
Gabapentin	Anti-epileptic agent	36
Gemcitabine	Nucleoside metabolic inhibitor	39
Gemzar		25
Humira		246
Ibrance	Kinase inhibitor	47
Ibuprofen	Nonsteroidal anti-inflammatory drug	232
Ifosfamide	Alkylating drug	28
Imbruvica	Kinase inhibitor	38
Infliximab	Tumor necrosis factor blocker	46
Ipilimumab	CTLA-4-directed blocking antibody	34
Irinotecan		67
Irinotecan hcl		40
Keytruda	Programmed death Receptor-1 blocking antibody	87
Kisqali	Kinase inhibitor	35
Letrozole	Aromatase inhibitor	35
Leucovorin calcium	Folate analog	44
Lipitor	HMG-CoA reductase inhibitor	25
Melphalan	Alkylating drug	46
Methotrexate	Folate analog metabolic inhibitor	175
Methotrexate sodium	Folate analog metabolic inhibitor	51
Methylprednisolone	Corticosteroid	80
Metoclopramide	Dopamine-2 receptor antagonist	40
Metronidazole	Nitroimidazole antimicrobial	27
Mycophenolate mofetil	Antimetabolite immunosuppressant	135
Mycophenolic acid	Antimetabolite immunosuppressant	26
Naproxen	Nonsteroidal anti-inflammatory drug	62
Nexium	Proton pump inhibitor	229
Nivolumab	Programmed death Receptor-1 blocking antibody	110
Omeprazole	Proton pump inhibitor	153
Opdivo	Programmed death Receptor-1 blocking antibody	66
Oxaliplatin	Platinum-based drug	180
Ozempic	GLP-1 receptor agonist	35
Paclitaxel	Microtubule inhibitor	232
Pantoprazole	Proton pump inhibitor	73
Pantoprazole sodium	Proton pump inhibitor	41
Paracetamol		34
Pembrolizumab	Programmed death Receptor-1 blocking antibody	75
Pemetrexed	Folate analog metabolic inhibitor	106
Pertuzumab	HER2/neu receptor antagonist	27
Plavix	P2Y12 platelet inhibitor	65
Pradaxa	Direct thrombin inhibitor	125
Prednisolone	Corticosteroid	94
Prednisone	Corticosteroid	264
Prilosec	Proton pump inhibitor	60
Prograf	Calcineurin inhibitor immunosuppressant	29
Prolia	RANK ligand inhibitor	32
Radiation Therapy		77
Radiotherapy		38
Remicade	Tumor necrosis factor blocker	87
Revlimid	Thalidomide analog	63
Rituximab	CD20-directed cytolytic antibody	111
Rivaroxaban	Factor Xa inhibitor	37
Seroquel	Atypical antipsychotic	27
Sertraline	Serotonin reuptake inhibitor	40
Simvastatin	HMG-CoA reductase inhibitor	29
Sutent	Kinase inhibitor	41
Tacrolimus	Calcineurin inhibitor immunosuppressant	109
Taxol		164
Taxotere		31
Temozolomide	Alkylating drug	47
Trastuzumab	HER2/neu receptor antagonist	50
Vedolizumab	Integrin receptor antagonist	48
Velcade	Proteasome inhibitor	52
Vincristine		89
Vincristine sulfate	Vinca alkaloid	27
Vinorelbine	Vinca alkaloid	28
Vioxx		104
Warfarin	Vitamin K antagonist	34
Xalkori	Kinase inhibitor	61
Xarelto	Factor Xa inhibitor	71
Xeljanz	Janus kinase inhibitor	56
Xeloda	Nucleoside metabolic inhibitor	61
Xyrem	Central nervous system depressant	25
Yervoy	CTLA-4-directed blocking antibody	34
Zometa		97

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 49 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Oesophagitis name, in order of name
Class	Reports with this term
Alkylating drug	375
Angiotensin 2 receptor blocker	134
Anthracycline topoisomerase inhibitor	162
Anti-epileptic agent	65
Antimetabolite immunosuppressant	176
Aromatase inhibitor	51
Atypical antipsychotic	174
beta-Adrenergic blocker	88
Bisphosphonate	429
Calcineurin inhibitor immunosuppressant	201
Calcium channel blocker	71
CD20-directed cytolytic antibody	151
Corticosteroid	662
CTLA-4-directed blocking antibody	68
Direct thrombin inhibitor	137
Epidermal growth factor receptor antagonist	143
Factor Xa inhibitor	230
Fluoroquinolone antibacterial	75
Folate analog metabolic inhibitor	375
GLP-1 receptor agonist	122
HER2/neu receptor antagonist	95
HMG-CoA reductase inhibitor	105
Integrin receptor antagonist	81
Interleukin-17A antagonist	58
Interleukin-4 receptor alpha antagonist	114
Janus kinase inhibitor	120
Kinase inhibitor	667
Lincosamide antibacterial	81
Loop diuretic	72
Microtubule inhibitor	383
Nonsteroidal anti-inflammatory drug	698
Nucleoside metabolic inhibitor	594
Opioid agonist	71
P2Y12 platelet inhibitor	197
Platinum-based drug	1,148
Programmed death Ligand-1 blocker	88
Programmed death Receptor-1 blocking antibody	401
Proteasome inhibitor	68
Proton pump inhibitor	671
Retinoid	55
Serotonin reuptake inhibitor	137
Tetracycline-class drug	257
Thalidomide analog	84
Thiazide diuretic	86
Topoisomerase inhibitor	278
Tumor necrosis factor blocker	283
Vascular endothelial growth factor inhibitor	291
Vinca alkaloid	61
Vitamin K antagonist	58

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Oesophagitis, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Oesophagitis
Age	Reports	Share
Under 2	29	0.3%
2 to 11	108	1%
12 to 17	208	1.9%
18 to 44	1,226	11.5%
45 to 64	2,735	25.6%
65 to 74	1,867	17.4%
75 and over	1,535	14.3%
Age not given	2,992	28%

Sex of the patient in the reports that record Oesophagitis
Sex	Reports	Share
Female	5,403	50.5%
Male	4,232	39.6%
Unknown or not given	1,065	10%

Age and sex are as the report gives them. 48.7% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Oesophagitis: adverse event reports that record this term. https://reportedreactions.com/reaction/oesophagitis/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Oesophagitis mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page